Ventricular Assist Devices Market Research Report Information By Product Type (Left Ventricular Assist Device, Right Ventricular Assist Device, Biventricular Assist Device), By Type of Flow (Continuous Flow, Pulsatile Flow), By Design (Implantable Ventricular Assist Device, Transcutaneous Ventricular Assist Device) and By Application (Destination Therapy, Bridging Therapy) – Forecast to 2032

Global Ventricular Assist Devices Market Overview

Ventricular Assist Devices Market Size was valued at USD 1.80 Billion in 2023. The Global Ventricular Assist Devices industry is projected to grow from USD 1.95 Billion in 2024 to USD 3.39 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.26% during the forecast period (2024 - 2032).

A ventricular assist device (VAD) is a miniaturized mechanical pump that is used to support heart function and maintain blood flow to vital organs in patients with weakened hearts. A ventricular assist device can be used if one or both the heart's ventricles don't function properly. Ventricular assist devices play an important role in managing patients with cardiac strokes and heart failures owing to the dearth of heart donors. Thus, there has been a huge demand for VAD and the market will witness an exponential growth during the forecast years.

Furthermore, the current outbreak of COVID-19 along with an increasing number of manufacturers in various regions is driving the ventricular assist devices market for ventricular assist devices.

June 2024:  Royal Philips, a prominent player in the field of health technology, has revealed the successful implementation of the Duo Venous Stent System. This device is designed to treat patients suffering from chronic venous insufficiency (CVI) by addressing venous outflow obstruction. The U.S. Food and Drug Association (FDA) has granted premarket approval (PMA) for this implantable medical device. Affecting a total of 25 million individuals worldwide, deep venous illness is caused by venous thromboembolism, a medical condition characterized by the formation of blood clots within the veins [2]. It ranks as the third most prevalent cardiovascular illness. The presence of deep venous architecture and blockages can give rise to a variety of intricate complexity and mechanical difficulties. The Duo Venous Stent System is specifically designed to meet the specific requirements of venous architecture and blockages. It consists of two stents, namely the Duo Hybrid and Duo Extend, which come in different sizes. The Duo Hybrid stent features a unique integrated design that integrates various zones with different mechanical qualities into a single structure [3]. When dealing with lengthy lesions, the Duo Extend treatment seamlessly combines with the Duo Hybrid to effectively extend therapy. These two stents are specifically engineered to function in tandem, reducing the likelihood of stent fracture and corrosion. Additionally, they offer the capability to stent within narrower caudal veins.

January 2024 Cleerly, a firm dedicated to establishing a higher level of medical attention for the detection of heart illness, has introduced Cleerly ISCHEMIA, a product that has just obtained permission from the U.S. Food and Drug Administration (FDA) as a medical device under the 510(k) category. The Cleerly ISCHEMIA analysis program is an automated tool that uses machine learning to provide decision support for diagnosing patients who are undergoing coronary computed tomography angiography (CCTA) analysis with Cleerly Labs software. Cleerly ISCHEMIA utilizes its artificial intelligence capabilities to assess the presence or absence of coronary artery ischemia by analyzing quantitative measurements of atherosclerosis, stenosis, and major vascular morphology derived from patients' CCTA images. When used by a healthcare physician who interprets medical data, this software, along with the findings from Cleerly Labs, offers individualized analysis that can be valuable in identifying probable ischemia related to coronary artery disease (CAD).

Market Influencer

Increasing demand for VADs owing to a shortage of heart donors drives the global ventricular assist devices market.

Ventricular Assist Devices Market Trends

Market Drivers

• Increasing prevalence of cardiovascular disorders- Cardiovascular diseases are the number one cause of deaths globally. According to the 2019 report of WHO, nearly 17.9 million people died due to cardiovascular diseases in 2018 which is about 31% of the total deaths. The increasing prevalence of these diseases is likely to create demand for VADs and push the ventricular assist devices market growth from 2020 to 2027.

• High burden of CVD on the healthcare system- 2019 CDC report states that CVD burden on the US health care system is nearly USD 214 billion each year

• Shortage of heart donors resulting in increased demand for VADs

• Development of technologically advanced products

• Increasing number of government initiatives to support medical device manufacturers

• A large number of clinical trials in VAD development. More than 200 clinical studies are being carried out across the globe as of June 2020. These clinical trials are being conducted by various companies, research organizations, and universities. Some of the major companies involved in these studies are Abbott, Medtronic, and Berlin Heart GmbH among others.

Market Restraints

• Risks associated with a VAD implantation procedure


• Unfavorable reimbursement framework

Ventricular Assist Devices Market Segment Insights

Ventricular Assist Devices Product Type Insights

• Left Ventricular Assist Device (LVAD): This segment accounted for the largest market share in the global ventricular assist devices market. A LVAD is a pump that is used for patients who have reached end-stage heart failure. LVAD is surgically implanted and helps the left ventricle pump blood to the rest of the body. This segment is the major revenue contributing factor in this market as the number of LVAD implantations heart failure patients is quite high as compared to RVAD. As a result, a number of companies have developed advanced products to improve treatment outcomes. For instance, Abbott has successfully implanted its HeartMate II LVAD in more than 26,600 patients till now.

• Right Ventricular Assist Device (RVAD): Right ventricular assist device supports the left ventricle of the heart and helps in pumping the blood into the pulmonary artery and to the lungs.

• Biventricular Assist Device: This technically is not a separate type of ventricular assist devices. However, when both the ventricles of a patient fail to function, both LVAD and RVAD are implanted into the patient at the same time which is called BIVAD.

Ventricular Assist Devices Type of Flow Insights

• Continuous Flow: Continuous flow left ventricular assist devices (CFVAD) are currently the most widely used type of VAD. CFVADs offer advantages of smaller size, increased reliability & durability, and subsequent improvements in survival. It accounts for the largest market share and is also the fastest-growing segment in the global ventricular assist devices market. Medtronic’s HeartWare is an example of a continuous flow of VAD.

• Pulsatile Flow: Pulsatile flow VADs use positive displacement pumps which mimics the natural pulsing action of the heart. They are relatively noisier, require regular maintenance and early replacement due to the continuous rotation of moving parts. Pulsatile flow VADs are less preferred compared to continuous flow, thus they are expected to exhibit a moderate ventricular assist devices market growth during the forecast period.

Ventricular Assist Devices Design Insights

• Implantable Ventricular Assist Device: This segment captured the largest market share in 2019. An implantable VAD has a design wherein its pump is implanted inside the body, and its power source is located outside the body. A cable connects the pump to the power source through a small hole in the abdomen. Implantable VADs are used when a patient is waiting for a heart transplant or as a long-term solution if a patient is not eligible for transplant procedure due to other medical complications.

• Transcutaneous Ventricular Assist Device: A transcutaneous VAD has design wherein both its pump and power source are located outside of the body. Tubes connect the pump to the heart through small holes in the abdomen. Transcutaneous VAD is generally used for short-term support during or after surgery.

Ventricular Assist Devices Application Insights

• Destination Therapy: It is an end-stage therapy where the VADs are implanted in severe heart failure patients, and in the patients, who are not eligible for the transplantation. The VADs remain in the patient’s body for the rest of their lifespan. With the increasing dearth of heart honors and heart failure patients, this is the segment contributes to the largest share in the global ventricular assist devices market.

• Bridging Therapy: Bridging therapy is growing at a significant rate. There are three subsets to this therapy. Bridge to transplantation; where the VADs are implanted until the patient is ready for the transplant procedure. Bridge to recovery; where the VADs are implanted post the transplantation which supports the patient’s heart while it recovers and starts normal functioning. Bridge to candidacy; where VADs are implanted in the patients who are sick till they come to a state of being eligible for transplantation procedure.

Ventricular Assist Devices Region Insights

• Americas: The Americas dominated the ventricular assist devices market in 2019 owing to the high number of patients suffering from cardiovascular diseases and less availability of heart donors. According to the CDC report published in 2017, nearly 6.5 million people have heart failure in the US each year. American Heart Association states that the number of people diagnosed with heart failure is increasing and projected to rise by 46% by 2030.

• Europe: Europe is projected to show exponential growth in the ventricular assist devices market. The high prevalence of the cardiovascular disease is the major factor pushing the growth of the ventricular assist devices market in the region. 2017 report of European Heart Network states that each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU). Besides, in Europe, there are companies like the Berlin Heart which are involved in the development of new products and providing treatment options for different age groups. For instance, in February 2020, Berlin Heart GmbH Company’s EXCOR Active has received CE marking and is now supporting pediatric heart patients in Germany.

• Asia-Pacific: the Asia Pacific is anticipated to witness significant growth rate over the forecast period owing due to increasing chronic cardiovascular diseases, rising healthcare expenditure, and a rise in the number of collaborations & strategic agreements among major market players. Moreover, increasing medical tourism for cardiac surgeries in countries like India, Malaysia, and Singapore among others is one major factor pushing the growth of the market in this region. Also, government initiatives such as “Make in India” are encouraging the local players to enter into the manufacturing of medical devices and boost the ventricular assist devices market growth.

• Middle East & Africa: The increasing rate of cardiovascular diseases in one of the major factors in VAD market growth in the region. The number of people dying from CVD is quite high in the Middle East. According to the report published by the Institute of Health Metrics and Evaluation in 2018, nearly 36% of deaths in UAE are caused by cardiovascular diseases. Moreover, the developing healthcare infrastructure and growing innovative product options for the aging population with heart conditions are also boosting the ventricular assist devices market growth in this region.

Key Players

• Medtronic plc


• Abbott


• Berlin Heart GmbH


• ReliantHeart Inc.


• Abiomed Inc.


• Cardiac Assist Inc.


• Cirtec


• CorWave SA


• Fineheart